IHS Chemical Week


Pharma/Fine Chemicals Roundup – October 11

7:19 AM MDT | October 11, 2011 | By DEEPTI RAMESH


Aesica Pharmaceuticals (Newcastle upon Tyne, U.K.), a provider of active pharmaceutical ingredients (APIs), formulations, and custom synthesis, says it has formed a manufacturing alliance with Noramco (Athens, GA), a manufacturer of opiate-derived APIs. The alliance involves a technical transfer of a process for the manufacture of codeine phosphate from a patented poppy supplied by Noramco’s affiliate, Tasmanian Alkaloids (Westbury, Australia), allowing for the conversion of the extracted alkaloid to a finished API in a one-step process for codeine phosphate. Noramco will sell codeine manufactured by Aesica through its European-based sales team.
Noramco will “supply the U.K. and other world markets from Aesica and have had very good response thus far from customers seeking a secure, integrated source of codeine and controlled ingredients,” says Leslie Storms, v.p./Global Sales at Noramco.


Active pharmaceutical ingredients (APIs) manufacturer ScinoPharm Taiwan (Shan-Hua, Taiwan) says it began trading its shares on the Taiwan Stock Exchange Board on September 29, 2011.
ScinoPharm contributes to 65% of the API exported from Taiwan, and is now a leading global producer of APIs for injectable anti-cancer treatments, the company says.
ScinoPharm recently expanded its facility in Taiwan including adding a peptide plant, and two large production lines are currently under construction. The first phase of a new facility at Changshu, China will be completed in this quarter, which includes a full scale R&D center, large production capacities of key intermediates as well as two API lines. It is expected that by the end of the 2012, the second phase of construction, mainly for the large API capacities, will be completed.


Ipca Laboratories (Mumbai), a manufacturer of active pharmaceutical ingredients (APIs) and formulations plans to acquire a pharmaceutical firm in Indonesia, which has a generic product marketing licence, reports say. Several companies have been shortlisted, and the deal is expected to be completed in the next few months.


AstraZeneca says it will invest $200 million in a new manufacturing facility, located in the China Medical City at Taizhou, Jiangsu Province, China. The new site, which represents AstraZeneca’s largest ever investment in a single manufacturing facility globally, will produce both intravenous and oral solid medicines. Construction is expected to be completed by the end of 2013.
The Chinese pharmaceutical market grew from $10 billion in 2004 to $41 billion in 2010 and, according to IMS, is expected to grow to over $100 billion by 2015, AstraZeneca says.
AstraZeneca’s reported more than $1 billion sales in China in 2010. “Our new manufacturing facility will complement our efforts to meet the medical needs of Chinese patients with medicines that are locally produced. In particular, it will help us to reach out to more of the estimated 900 million people in urban and rural communities who have had less access to high quality medicines,” says Mark Mallon, President, AstraZeneca China.

contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa